🫀 Pediatric Electrophysiology
Pacemakers in Children
Indications, Device Selection, Lead Considerations, Programming & Long-Term Outcomes in Pediatric Pacing
~1,500
Pediatric implants/yr (US)
CHB: 1/22,000
Congenital CHB incidence
5–8 years
Average generator lifespan
Micra™ AVC
Leadless pacing in CHD
📋 Contents
- Overview — Why Pediatric Pacing is Unique
- Indications for Permanent Pacing
- Congenital Complete Heart Block
- Surgical/Acquired CHB
- Device Selection & Lead Considerations
- Programming Principles in Children
- ACC/AHA/PACES Guidelines
- Long-Term Outcomes & Complications
- Leadless & Subcutaneous ICD in Children
🔬 Why Pediatric Pacing is Unique
Pacing in children is fundamentally different from adult pacing. Children must accommodate decades of somatic growth, have distinct anatomy (venous size, cardiac dimensions), require higher pacing rates than adults, and have unique indications driven by congenital heart disease and fetal/neonatal presentations.
🔑 Key Differences from Adult Pacing
- Growth: leads must accommodate decades of somatic growth → active fixation preferred
- Heart rate requirements: higher (infant LR 80–100 bpm vs. adult 60 bpm)
- Venous access: small-caliber veins in neonates/infants → epicardial leads often required
- Multiple reoperations expected: ~5–8 years per generator
- Long-term TV regurgitation risk from transvenous RV leads
- Unique indications: congenital CHB, post-op CHD, channelopathy prophylaxis
📊 Epidemiology of Pediatric Pacing
- ~1,500 new pediatric pacemaker implants per year (US)
- ~600 ICD implants per year in patients <21 years
- Median age at implant: 8–10 years
- Congenital CHB: most common indication in neonates
- Post-op CHB: most common in older children
- Predicted lifetime pacing: 50–70+ years for neonates implanted today
📋 Indications for Permanent Pacing
🤱 Congenital Complete Heart Block (CCHB)
CCHB occurs in approximately 1:15,000–22,000 live births. It is most commonly caused by transplacental passage of maternal anti-Ro/SSA and anti-La/SSB antibodies (associated with maternal SLE/Sjögren’s) in ~85% of immune-mediated cases, and by structural CHD (L-TGA, AV canal) in ~15%.
Immune-Mediated CCHB (Anti-Ro/La)
- Occurs in 1–2% of anti-Ro positive pregnancies
- Once CHB established: irreversible in >95%
- Dexamethasone in utero: may prevent progression from 2nd → 3rd degree
- IVIG in utero: no proven benefit for established CHB
- Hydrops fetalis + CHB: mortality up to 40–50%
- In utero pacing: investigational; high risk
- Recurrence risk in subsequent pregnancies: 15–20%
CCHB — When to Implant?
- Symptomatic neonates: urgent implant regardless of age/weight
- Asymptomatic: rate <55 bpm → implant
- Rate 55–70 bpm with CHD: implant
- Rate >70 bpm, narrow QRS, normal LV function: observe
- Smallest published successful implant: ~2.5 kg (epicardial)
- Minimum weight for transvenous approach: typically >10–15 kg
- CCHB + prolonged QT: implant irrespective of rate
📊 CCHB Natural History & Outcomes (Swedish Registry, n=102)
Without pacing: 10-year survival ~50% (largely based on older data). With pacing: survival approaches age-matched controls. Risk of SCD before pacing: estimated 6–9%. Tachycardia-mediated cardiomyopathy with VVIR pacing (no AV synchrony): LV dilation in 10–15% over 10 years → upgrade to dual-chamber or biventricular pacing recommended. (Baruteau et al., Heart Rhythm 2016)
Without pacing: 10-year survival ~50% (largely based on older data). With pacing: survival approaches age-matched controls. Risk of SCD before pacing: estimated 6–9%. Tachycardia-mediated cardiomyopathy with VVIR pacing (no AV synchrony): LV dilation in 10–15% over 10 years → upgrade to dual-chamber or biventricular pacing recommended. (Baruteau et al., Heart Rhythm 2016)
1–2%
Anti-Ro+ pregnancies → CCHB
85%
CCHB cases are immune-mediated
15–20%
Recurrence risk in subsequent pregnancies
40–50%
Mortality if CCHB + hydrops
🏥 Surgical / Acquired Heart Block
📊 Post-Surgical AV Block — Important Data
Surgically acquired CHB affects approximately 1–3% of all cardiac operations (highest risk: VSD closure 1–5%, AV canal repair 5–10%, LVOTO relief 2–4%, congenitally corrected TGA repair). Approximately 50% resolve within 7 days — watchful waiting with temporary pacing is therefore appropriate for the first week. Persistent CHB beyond 7–10 days: permanent pacemaker implant is standard recommendation. Spontaneous recovery after 7 days is rare (<5%). (Bruckheimer et al.; Pediatric Cardiac Care Consortium data)
Surgically acquired CHB affects approximately 1–3% of all cardiac operations (highest risk: VSD closure 1–5%, AV canal repair 5–10%, LVOTO relief 2–4%, congenitally corrected TGA repair). Approximately 50% resolve within 7 days — watchful waiting with temporary pacing is therefore appropriate for the first week. Persistent CHB beyond 7–10 days: permanent pacemaker implant is standard recommendation. Spontaneous recovery after 7 days is rare (<5%). (Bruckheimer et al.; Pediatric Cardiac Care Consortium data)
| Operation | AV Block Incidence | Permanent Pacemaker Rate |
|---|---|---|
| VSD closure (perimembranous) | 1–5% | 0.5–2% |
| Complete AV canal repair | 5–10% | 2–5% |
| LVOTO (subaortic) resection | 2–4% | 1–2% |
| Congenitally corrected TGA repair | 5–20% | 5–15% |
| Fontan procedure (all types) | 1–3% | 0.5–2% |
| Tricuspid valve repair/replacement | 2–5% | 1–3% |
| TOF repair | 0.5–1% | 0.1–0.5% |
Sinus Node Disease in CHD — Late Complication
Sinus node dysfunction (SND) is a common late sequela of atrial surgery, particularly Mustard/Senning repairs for TGA, Fontan procedures, and sinus venosus ASD repair. SND manifests as bradycardia-tachycardia syndrome, chronotropic incompetence, and sinus arrest.
Mustard/Senning — Sinus Node Disease
- SND incidence: 40–70% at 20 years post-op
- Loss of sinus rhythm: 30–50% by 20 years
- Bradycardia-tachycardia syndrome: common
- May require pacing AND antiarrhythmic therapy
- DDIR mode with rate-responsive pacing optimal
- Associated risk of SCD: 0.5–1.5%/year long-term
Fontan — SND & Arrhythmias
- SND: 10–20% at 10 years post-Fontan
- IART/AFL: 30–50% by 20 years
- Pacemaker may be needed for AV synchrony
- Fenestrated Fontan: transvenous approach possible
- Lateral tunnel: often requires epicardial system
- Rhythm disturbances: major cause of Fontan failure
⚙️ Device Selection & Lead Considerations
Epicardial vs. Transvenous — The Fundamental Choice
| Feature | Epicardial System | Transvenous System |
|---|---|---|
| Age/weight threshold | Any age, any weight | Generally >10–15 kg; >5 years old |
| Lead access | Sternotomy or thoracotomy required | Percutaneous; subclavian/axillary vein |
| Lead lifespan | 5–10 years (inferior sensing/pacing over time) | 10–15 years |
| AV synchrony | Possible with dual epicardial leads | Standard with DDD mode |
| Sensing performance | Lower/variable | Superior and stable |
| TV regurgitation risk | None | 5–10% significant TR over time |
| Lead extraction | Requires sternotomy | Percutaneous extraction possible |
| Best for | Neonates/infants, complex CHD, univentricular hearts | Older children, biventricular hearts, straightforward anatomy |
Lead Considerations in Growing Children
Transvenous Lead Tips
- Active-fixation leads preferred (accommodate growth)
- Leave adequate slack (“J-loop”) in RA for growth
- Subclavian/axillary route: lower risk of subclavian crush than subclavian only
- Right-sided approach: avoid left subclavian in potential future ICD candidates
- Venous access preservation: crucial for future lead additions
- MRI-conditional leads: strongly preferred for lifetime compatibility
Epicardial Lead Tips
- Steroid-eluting leads (Medtronic 4968, 4965): lower threshold over time
- Place pacing leads on RV free wall — avoids conduction system
- Bipolar epicardial leads preferred for sensing
- Leave looped lead in pericardial space for growth
- Generator pocket: subpectoral (neonates); submammary (older girls)
- Non-steroid epicardial leads: historically high exit block incidence (10–20%)
🖥️ Programming Principles in Children
Pacing Modes
| Mode | Description | Best Used For |
|---|---|---|
| DDD | Dual-chamber sensing and pacing; AV synchrony maintained | AV block with intact sinus node; standard mode for older children |
| DDDR | DDD + rate-response (activity/minute ventilation sensor) | Chronotropic incompetence (post-Mustard, SND) |
| VVI/VVIR | Single-chamber ventricular; no AV synchrony | AF/flutter with complete AV block; simple epicardial system |
| AAI/AAIR | Atrial pacing only; relies on intact AV conduction | SND with normal AV node function (rare in CHD) |
| DOO | Asynchronous dual-chamber; fixed rate | Electromagnetic interference environments; electrocautery |
Rate Programming by Age
| Age Group | Lower Rate Limit | Upper Tracking Rate | AV Delay |
|---|---|---|---|
| Neonates / Infants <1yr | 80–100 bpm | 160–180 bpm | 100–120 ms |
| Infants 1–3 years | 70–90 bpm | 150–170 bpm | 110–130 ms |
| Children 3–10 years | 60–80 bpm | 140–160 bpm | 120–150 ms |
| Adolescents >10 years | 50–70 bpm | 130–150 bpm | 140–170 ms |
| Athlete modification | 45–55 bpm | 170–180 bpm | Age-appropriate |
💡 Programming Pearls for Pediatric Pacing
(1) RV pacing minimization: Prolonged RV pacing causes LV dyssynchrony → pacing-induced cardiomyopathy in 5–10% over 10 years. Use programmed long AV delays or MVP (Managed Ventricular Pacing) algorithms to minimize RV pacing percentage.
(2) LV pacing or BiV: If LV dysfunction develops with RV pacing, upgrade to cardiac resynchronization therapy (CRT). QRS ≥150ms with LBBB morphology from RV pacing is the key trigger.
(3) Safety margin: Program output at 2–3× pacing threshold (minimum 2.5V at 0.5ms for epicardial; 1.5V for transvenous — higher thresholds expected epicardial).
(1) RV pacing minimization: Prolonged RV pacing causes LV dyssynchrony → pacing-induced cardiomyopathy in 5–10% over 10 years. Use programmed long AV delays or MVP (Managed Ventricular Pacing) algorithms to minimize RV pacing percentage.
(2) LV pacing or BiV: If LV dysfunction develops with RV pacing, upgrade to cardiac resynchronization therapy (CRT). QRS ≥150ms with LBBB morphology from RV pacing is the key trigger.
(3) Safety margin: Program output at 2–3× pacing threshold (minimum 2.5V at 0.5ms for epicardial; 1.5V for transvenous — higher thresholds expected epicardial).
Pacing-Induced Cardiomyopathy (PIC)
⚠️ PIC — An Underrecognized Complication
Chronic RV apical pacing → LV mechanical dyssynchrony → dilated cardiomyopathy in 5–15% over 10 years in children. Risk factors: high percentage of RV pacing (>40%), young age at implant, pre-existing LV dysfunction, LBBB morphology during pacing. Management: switch to His-bundle pacing (HBP), left bundle branch pacing (LBBP), or full CRT. His-bundle pacing achieves physiological ventricular activation — increasingly used in pediatric pacing. (Cano et al., JACC 2020)
Chronic RV apical pacing → LV mechanical dyssynchrony → dilated cardiomyopathy in 5–15% over 10 years in children. Risk factors: high percentage of RV pacing (>40%), young age at implant, pre-existing LV dysfunction, LBBB morphology during pacing. Management: switch to His-bundle pacing (HBP), left bundle branch pacing (LBBP), or full CRT. His-bundle pacing achieves physiological ventricular activation — increasingly used in pediatric pacing. (Cano et al., JACC 2020)
📋 ACC/AHA/PACES Guidelines — Key Recommendations
Source: 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients with Bradycardia and Cardiac Conduction Delay | PACES/HRS Expert Consensus 2021 on Pacing in Pediatric Patients
CLASS I LOE C
Permanent pacemaker implantation is indicated for symptomatic sinus node dysfunction or advanced AV block in children when the arrhythmia is documented and symptoms attributed to the bradycardia.
ACC/AHA 2018 Bradycardia Guideline
CLASS I LOE B
Permanent pacing is recommended for congenital CHB with a wide QRS escape rhythm, complex ventricular ectopy, or ventricular dysfunction regardless of symptoms.
ACC/AHA 2018 Bradycardia Guideline; Friedman et al., JACC 2021
CLASS I LOE B
Permanent pacing is recommended for post-operative advanced 2nd or 3rd degree AV block that is not expected to resolve or has persisted for at least 7 days after cardiac surgery.
ACC/AHA 2018 Bradycardia Guideline
CLASS IIa LOE C
Dual-chamber pacing is reasonable (preferred over single-chamber ventricular pacing) in children with AV block when hemodynamics would benefit from AV synchrony, and venous access permits safe lead placement.
PACES/HRS Expert Consensus 2021
CLASS IIa LOE C
His-bundle pacing or left bundle branch area pacing is reasonable as an alternative to RV pacing in children who require high burden ventricular pacing, to minimize risk of pacing-induced cardiomyopathy.
PACES/HRS Expert Consensus 2021
📊 Long-Term Outcomes & Complications
| Complication | Epicardial | Transvenous | Time Frame |
|---|---|---|---|
| Lead failure / exit block | 10–20% (non-steroid); 5–8% (steroid-eluting) | 2–5% | 5–10 years |
| Lead dislodgement | 2–5% | 1–3% (early) | Acute |
| Infection (pocket/device) | 1–3% | 1–2% | Anytime |
| Generator replacement (longevity) | Every 5–7 yrs | Every 7–10 yrs | Lifelong |
| TV regurgitation | None | 5–10% significant | 10+ years |
| Venous occlusion | N/A | 5–20% subclavian occlusion | 5–10 years |
| Pacing-induced cardiomyopathy | 5–10% (with RV pacing) | 5–15% (with RV pacing) | 10+ years |
| Pneumothorax (transvenous) | N/A | 1–2% | Acute |
📊 Pediatric Pacemaker Long-Term Data (n=650, median follow-up 12 years)
Cumulative event-free survival from lead failure: 85% at 10 years, 70% at 15 years for transvenous leads. Epicardial steroid-eluting leads: lead survival 80% at 10 years, similar to transvenous. Re-operation rate (lead/generator): 60% of patients required at least one reoperation by 15 years. Pacing-induced cardiomyopathy identified in 8% at 12-year follow-up — majority reversible with CRT upgrade. (Fortescue et al., Pacing Clin Electrophysiol 2004; updated PACES registry 2018)
Cumulative event-free survival from lead failure: 85% at 10 years, 70% at 15 years for transvenous leads. Epicardial steroid-eluting leads: lead survival 80% at 10 years, similar to transvenous. Re-operation rate (lead/generator): 60% of patients required at least one reoperation by 15 years. Pacing-induced cardiomyopathy identified in 8% at 12-year follow-up — majority reversible with CRT upgrade. (Fortescue et al., Pacing Clin Electrophysiol 2004; updated PACES registry 2018)
🔬 Leadless Pacing & S-ICD in Children
Leadless Pacemakers (Micra AV, Micra VR)
The Micra Transcatheter Pacing System (Medtronic) is a fully self-contained pacemaker implanted directly into the RV via femoral vein. No leads, no pocket. FDA-approved for adults; pediatric use is off-label but growing.
Micra Advantages in CHD
- No lead-related complications (TV regurgitation, fracture)
- No pocket → no pocket infections
- Ideal for univentricular hearts with systemic RV
- Retrievable if needed (up to 6 weeks post-implant)
- Smallest reported case: 15 kg (case reports)
- Micra AVC: can provide AV synchrony via accelerometer
Subcutaneous ICD (S-ICD) in Children
- No transvenous lead → no TV regurgitation, no lead extraction
- Minimum weight: ~20–25 kg (body habitus-dependent)
- Sense vectors mapped pre-implant — mandatory screening
- Cannot pace (for pacing + defibrillation needs: hybrid approach)
- SIDS-like phenotype high-risk: LQTS, Brugada, HCM
- ICD shock rates: 5–8%/year appropriate; 5–10% inappropriate
📊 S-ICD Pediatric Registry (n=218, median age 18 years)
Appropriate shock rate: 7.3%/patient-year. Inappropriate shock rate: 7.9%/patient-year (predominantly T-wave oversensing and supraventricular tachycardia). Complication requiring reoperation: 5.5%. Freedom from device-related complication at 3 years: 90%. S-ICD is particularly attractive for young patients with channelopathies (LQTS, Brugada, CPVT) where lifetime device management is a priority. (EFFORTLESS S-ICD Registry; Levy et al., JACC 2017)
Appropriate shock rate: 7.3%/patient-year. Inappropriate shock rate: 7.9%/patient-year (predominantly T-wave oversensing and supraventricular tachycardia). Complication requiring reoperation: 5.5%. Freedom from device-related complication at 3 years: 90%. S-ICD is particularly attractive for young patients with channelopathies (LQTS, Brugada, CPVT) where lifetime device management is a priority. (EFFORTLESS S-ICD Registry; Levy et al., JACC 2017)
His-Bundle Pacing & Left Bundle Branch Pacing (LBBP)
Physiological pacing via the His bundle or left bundle branch area is a rapidly advancing technique that achieves near-normal ventricular activation, eliminating the long-term risk of pacing-induced cardiomyopathy. Early pediatric series show feasibility with comparable thresholds to RV pacing, and the technique is increasingly adopted at major centers as an alternative to RV apical pacing in children expected to have high-burden ventricular pacing for decades.
